Treatment of cancer chemotherapy-induced toxicity with the pineal hormone melatonin
Experimental data have suggested that the pineal hormone melatonin (MLT) may counteract chemotherapy-induced myelosuppression and immunosuppression. In addition, MLT has been shown to inhibit the production of free radicals, which play a part in mediating the toxicity of chemotherapy. A study was therefore performed in an attempt to evaluate the influence of MLT on chemotherapy toxicity. The study involved 80 patients with metastatic solid tumors who were in poor clinical condition (lung cancer: 35; breast cancer: 31; gastrointestinal tract tumors: 14). Lung cancer patients were treated with cisplatin and etoposide, breast cancer patients with mitoxantrone, and gastrointestinal tract tumor patients with 5-fluorouracil plus folates. Patients were randomised to receive chemotherapy alone or chemotherapy plus MLT (20 mg/day p.o. in the evening). Thrombocytopenia was significantly less frequent in patients concomitantly treated with MLT. Malaise and asthenia were also significantly less frequent in patients receiving MLT. Finally, stomatitis and neuropathy were less frequent in the MLT group, albeit without statistically significant differences. Alopecia and vomiting were not influenced by MLT. This pilot study seems to suggest that the concomitant administration of the pineal hormone MLT during chemotherapy may prevent some chemotherapy-induced side-effects, particularly myelosuppression and neuropathy. Evaluation of the impact of MLT on chemotherapy efficacy will be the aim of future clinical investigations.
Key wordsChemotherapy Melatonin Myelosuppression Toxicity
Unable to display preview. Download preview PDF.
- 1.Arendt J (1988) Melatonin. Clin Endocrinol 29:205–229Google Scholar
- 2.Hill SM, Spriggs LL, Simon MA, Muraoka H, Blask DE (1992) The growth inhibitory action of melatonin on human breast cancer is linked to the oestrogen response system. Cancer Lett 64:249–256Google Scholar
- 3.Hrushesky WJM, Langer R, Theeuwes F (1991) Temporal control of drug delivery. Ann N Y Acad Sci 618:641–645Google Scholar
- 4.Lissom P, Barni S, Tancini G, et al (1994) A randomised study with subcutaneous low-dose interleukin-2 alone vs interleukin-2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma. Br J Cancer 69:196–199Google Scholar
- 5.Maestroni GJM, Conti A, Pierpaoli W (1988) Pineal melatonin, its fundamental immunoregulatory role in aging and cancer. Ann N Y Acad Sci :140–148Google Scholar
- 6.Maestroni GJM, Conti A, Lissom P (1994) Colony-stimulating activity and hematopoietic rescue from cancer chemotherapy compounds are induced by melatonin via endogenous interleukin-4.Cancer Res 54:4740–4744Google Scholar
- 7.Poeggler B, Reiter RJ, Tan DX, Chen LD, Manchester LC (1993) Melatonin, hydroxyl radical-mediated oxidative damage, and aging: a hypothesis. J Pineal Res 14:151–168Google Scholar
- 8.Regelson W, Pierpaoli W (1987) Melatonin: a rediscovered antitumor hormone? Its relation to surface receptors, sex, steroid metabolism, immunologic response and chronobiological factors in tumor growth and therapy. Cancer Invest 5:379–385Google Scholar
- 9.Smythe GA, Stuart MC, Lazarus I (1974) Stimulation and suppression of somatomedin activity by serotonin and melatonin. Experientia 30:1356–1358Google Scholar
- 10.Viviani S, Negretti E, Orazi A, et al (1990) Preliminary studies on melatonin in the treatment of myelodysplastic syndromes following cancer chemotherapy. J Pineal Res 8:347–351Google Scholar